Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine‐needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutation in pulmonary adenocarcinoma is clinically important due to its association with resistance to EGFR inhibitors and poor prognosis. To our knowledge, there has not been a comparative study focusing on cytological nuclear features of pulmonary adenocarcinoma harboring KRAS mutation (KRAS‐AD). Hence, we compared the cytomorphology of metastatic KRAS‐AD and EGFR‐positive adenocarcinoma (EGFR‐AD) in aspiration specimens from lymph nodes.

[1]  Ho Yun Lee,et al.  Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy. , 2014, Anticancer research.

[2]  J. Ahn,et al.  Micropapillary Mucinous Adenocarcinoma of the Lung: A Brief Case Report , 2013, Korean journal of pathology.

[3]  A. Moreira.  Subtyping of pulmonary adenocarcinoma in cytologic specimens , 2013, Cancer cytopathology.

[4]  S. Monaco,et al.  Cytologic subtyping of lung adenocarcinoma by using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification , 2013, Cancer Cytopathology.

[5]  R. Pearson,et al.  Targeting RNA polymerase I transcription and the nucleolus for cancer therapy , 2013, Expert opinion on therapeutic targets.

[6]  S. Ha,et al.  Cytologic Features of ALK-Positive Pulmonary Adenocarcinoma , 2013, Korean journal of pathology.

[7]  M. Ladanyi,et al.  KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma , 2013, Modern Pathology.

[8]  B. Parasuraman,et al.  EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital , 2013, PloS one.

[9]  G. Sauter,et al.  Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer. , 2013, Experimental and molecular pathology.

[10]  M. Ladanyi,et al.  Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas , 2013, Cancer.

[11]  D. Park,et al.  Ciliated adenocarcinomas of the lung: a tumor of non-terminal respiratory unit origin , 2012, Modern Pathology.

[12]  Liang Cheng,et al.  Molecular pathology of lung cancer: key to personalized medicine , 2012, Modern Pathology.

[13]  C. Sima,et al.  Predicting pulmonary adenocarcinoma outcome based on a cytology grading system , 2012, Cancer cytopathology.

[14]  Joon-Oh Park,et al.  Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy , 2011, Molecular Cancer Therapeutics.

[15]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  Y. Yatabe.  EGFR mutations and the terminal respiratory unit , 2010, Cancer and Metastasis Reviews.

[17]  Y. Ishikawa,et al.  Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? , 2010, Archives of pathology & laboratory medicine.

[18]  I. Yoshino,et al.  Role of endobronchial ultrasound-guided transbronchial needle aspiration in the management of lung cancer , 2008, General thoracic and cardiovascular surgery.

[19]  A. Iafrate,et al.  Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma , 2007, Diagnostic cytopathology.